Stress assessment in occupational medicine using a visual analogue scale

Les risques psychosociaux prennent une part de plus en plus prégnante en matière de santé au travail. Le médecin du travail doit pouvoir disposer d'outil permettant d'évaluer l'état de santé des salariés. L'évaluation du stress, conséquence et facteur de risque à la fois est un marqueur particulièrement intéressant pour le médecin du travail. Ce travail vise à éclairer l'utilisateur sur les qualités psychométriques de l'échelle visuelle analogique (EVA) dans l'évaluation du stress, dans le cadre de la médecine du travail. Nous avons étudié la stabilité, la fidélité interjuge, la validité concourante, la sensibilité discriminative, mais aussi les facteurs cognitifs pouvant influencer la réponse à l'EVA tels que la présentation de Soi, la revendication, ou la représentation sociale du stress. Nous proposons aussi des modalités d'utilisation et d'interprétation de l'EVA.Psychosocial risk factors are more and more important in the field of occupational health. Occupational physicians must have some useful tools to assess the mental health. Stress assessment may be an interesting marker for the occupational physicians. One way to assess the stress is the visual analogue scale, well known in pain assessment. But what about its psychometric properties? What about the stability, inter judge reliability, fiability, agreement between visual analogue scale and perceived stress scale, discriminative sensitivity? What is the influence of cognitive factors, such as the presentation of self, the claimings, and the social representation of stress? This manuscript is a guideline of stress assessment using a visual analogue scale too

Evaluation de l'état de santé d'artisans et de commerçants

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Evaluation de l'état de santé des artisans du bois

REIMS-BU Santé (514542104) / SudocSudocFranceF

Pathologie des musiciens instrumentistes à vent

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Insertion professionnelle de salariés atteints d'une pathologie mentale sévère

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Impact de la Rémunération sur Objectifs de Santé Publique sur le nombre annuel de dosage de l'hémoglobine A glycosylée en médecine générale entre 2011 et 2012

REIMS-BU Santé (514542104) / SudocSudocFranceF

"Evaluation du bien-être au travail"

REIMS-BU Santé (514542104) / SudocSudocFranceF

High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease

International audienceBackground & AimsLittle is known about the magnitude of the risk of anal and rectal cancer in patients with anal and/or perineal Crohn’s disease. We aimed to assess the risk of anal and rectal cancer in patients with Crohn’s perianal disease followed up in the Cancers Et Surrisque Associé aux Maladies Inflammatoires Intestinales En France (CESAME) cohort.MethodsWe collected data from 19,486 patients with inflammatory bowel disease (IBD) enrolled in the observational CESAME study in France, from May 2004 through June 2005; 14.9% of participants had past or current anal and/or perianal Crohn’s disease. Subjects were followed up for a median time of 35 months (interquartile range, 29–40 mo). To identify risk factors for anal cancer in the total CESAME population, we performed a case-control study in which participants were matched for age and sex.ResultsAmong the total IBD population, 8 patients developed anal cancer and 14 patients developed rectal cancer. In the subgroup of 2911 patients with past or current anal and/or perianal Crohn’s lesions at cohort entry, 2 developed anal squamous-cell carcinoma, 3 developed perianal fistula–related adenocarcinoma, and 6 developed rectal cancer. The corresponding incidence rates were 0.26 per 1000 patient-years for anal squamous-cell carcinoma, 0.38 per 1000 patient-years for perianal fistula–related adenocarcinoma, and 0.77 per 1000 patient-years for rectal cancer. Among the 16,575 patients with ulcerative colitis or Crohn’s disease without anal or perianal lesions, the incidence rate of anal cancer was 0.08 per 1000 patient-years and of rectal cancer was 0.21 per 1000 patient-years. Among factors tested by univariate conditional regression (IBD subtype, disease duration, exposure to immune-suppressive therapy, presence of past or current anal and/or perianal lesions), the presence of past or current anal and/or perianal lesions at cohort entry was the only factor significantly associated with development of anal cancer (odds ratio, 11.2; 95% CI, 1.18-551.51; P = .03).ConclusionsIn an analysis of data from the CESAME cohort in France, patients with anal and/or perianal Crohn’s disease have a high risk of anal cancer, including perianal fistula–related cancer, and a high risk of rectal cancer